Tumor immunotherapy: inching toward the finish line
AUTOR(ES)
Curiel, Tyler J.
FONTE
American Society for Clinical Investigation
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=150867Documentos Relacionados
- Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines
- Cancer immunotherapy: avoiding the road to perdition
- The finish line
- Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists
- Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?